BWX Technologies, Inc.

BWX Technologies, Inc. is a specialty manufacturer of nuclear components, a developer of nuclear technologies and a service provider with an operating history of more than 100 years. Its core businesses focus on the design, engineering and manufacture of precision naval nuclear components, nuclear reactors and nuclear fuel for the U.S. Government. The company also provides special nuclear materials processing, environmental site restoration services, products and services to customers in the nuclear power industry, critical medical radioisotopes and radiopharmaceuticals and other advanced nuclear technologies. The company operates in capital-intensive industries and relies on large contracts for a substantial amount of its revenues.

The company's Government Operations segment has specialized technical capabilities that have allowed it to be a valued supplier of nuclear components and fuel for the U.S. Government's naval nuclear fleet since the 1950s. Because of the technical and regulatory standards required to meet U.S. Government contracting requirements for nuclear components and fuel and the barriers to entry present in this type of environment, competition is limited. Primary competitors named in the filing for the Government Operations segment include Bechtel National, Inc., Amentum Environment & Energy, Inc., Fluor Corporation, Northrop Grumman Corporation, Huntington Ingalls Industries, Inc., Honeywell International, Inc., Leidos, Inc., Westinghouse Electric Corporation and AtkinsRéalis. For the Commercial Operations segment, primary competitors include Framatome, Cameco Corporation, Doosan Heavy Industries & Construction Co., Ltd., AECON Group Inc., Westinghouse Electric Corporation and AtkinsRéalis. In the medical radioisotopes area, competitors include Curium Pharma, SHINE Technologies and Jubilant DraxImage Inc.

The company generates revenue through two reportable segments: Government Operations and Commercial Operations. Revenue is generally recognized over time based on the measurement of the extent of progress toward completion using total costs incurred as a percentage of the total estimated project costs for individual performance obligations. The company executes contracts through a variety of methods, including fixed-price incentive fee, cost-plus, cost-reimbursable, firm fixed-price or some combination of these methods. The largest and primary customer of the Government Operations segment is the U.S. Government, which represented approximately 68% ¹ of total consolidated revenues for the year ended December 31, 2025.

The Government Operations segment engineers, designs and manufactures precision naval nuclear components, reactors and nuclear fuel for the U.S. Department of Energy/National Nuclear Security Administration's Naval Nuclear Propulsion Program and has over 100 years of experience in supplying components for defense applications. This segment also supplies proprietary and sole-source valves, manifolds and fittings to global naval and commercial shipping customers, downblends Cold War-era government stockpiles of high-enriched uranium, develops capabilities related to the manufacture of high-purity depleted uranium and manufactures other advanced materials and products for commercial, military and space applications. This segment also provides various services to the U.S. and Canadian governments by managing and operating high-consequence operations at U.S. nuclear weapons sites, national laboratories and manufacturing complexes, and is a leader in the development of advanced nuclear reactors for a variety of power and propulsion applications in the space and terrestrial domains. For the year ended December 31, 2025, Government Operations segment revenues were $2,350,090,000 ² and operating income was $394,850,000 ³.

The Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. This segment is the only commercial heavy nuclear component manufacturer in North America and is also a leading supplier of nuclear fuel, fuel handling systems, reactor controls, specialty tooling, nuclear-grade materials and precisely machined components, and related engineering and maintenance services for nuclear power plants. This segment also manufactures and supplies products for diagnostic imaging and radiotherapeutic treatments and is a partner for contract development and manufacturing services for life science and pharmaceutical companies, including the manufacture of medical radioisotopes, radiopharmaceuticals and medical devices. For the year ended December 31, 2025, Commercial Operations segment revenues were $853,070,000 ⁴ and operating income was $57,728,000 ⁵.

On January 3, 2025, the company completed the acquisition of Aerojet Ordnance Tennessee, Inc. (A.O.T), a subsidiary of L3Harris Technologies, Inc., for approximately $101.1 million ⁶, subject to certain working capital adjustments, which reflected a $2.2 million ⁷ reduction in the initial purchase price. On May 20, 2025, the company completed the acquisition of Kinectrics Holdings, Inc., the parent company of Kinectrics, Inc., for approximately CAD $782.7 million ⁸ subject to certain working capital and other adjustments, resulting in purchase consideration of CAD $614.5 million ($440.6 million ⁹ U.S. dollar equivalent), which is net of assumed pension liabilities, other postretirement benefit obligations and indebtedness. In November 2025, the company issued $1.25 billion ¹⁰ aggregate principal amount of 0% Convertible Senior Notes due 2030 (the 2030 Notes), including the exercise in full of the initial purchasers' option to purchase up to an additional $150.0 million ¹¹ principal amount of the 2030 Notes. The company paid $131.9 million ¹² to enter into privately negotiated capped call transactions. On November 10, 2025, the company entered into a New Credit Facility that includes a $1.25 billion ¹³ senior secured revolving credit facility. During the year ended December 31, 2025, the company paid $92.5 million ¹⁴ in dividends to holders of common stock and repurchased $30.0 million ¹⁵ of common stock.

Consolidated revenues increased 18.3% ¹⁶, or $494.8 million ¹⁷, to $3,198,425,000 ¹⁸ in the year ended December 31, 2025 compared to $2,703,654,000 ¹⁹ in 2024. Consolidated operating income increased $23.9 million ²⁰ to $404,459,000 ²¹ in the year ended December 31, 2025 compared to $380,607,000 ²² in 2024. Net income attributable to BWX Technologies, Inc. was $328,945,000 ²³ for the year ended December 31, 2025 compared to $281,941,000 ²⁴ in 2024. Diluted earnings per share was $3.58 ²⁵ for the year ended December 31, 2025 compared to $3.07 ²⁶ in 2024. Net cash provided by operating activities was $479,848,000 ²⁷ for the year ended December 31, 2025 compared to $408,428,000 ²⁸ in 2024.

The company expects to recognize approximately 40% ²⁹ of the revenue associated with its backlog by the end of 2026, with the remainder to be recognized thereafter. At December 31, 2025, ending backlog was $7,260.7 million ³⁰, which included $2,151.3 million ³¹ of unfunded backlog related to U.S. Government contracts. The value of unexercised options excluded from backlog as of December 31, 2025 was approximately $2,800 million ³², with $1,400 million ³³ expected to be awarded in 2026, $900 million ³⁴ expected to be awarded in 2030 and $500 million ³⁵ expected to be awarded in 2035, subject to Congressional appropriations.

The Government Operations segment's revenues are largely a function of national security spending by the U.S. Government. In March 2024, the U.S. Navy issued its 30-year shipbuilding plan containing three alternative procurement profiles based upon varied funding assumptions, all three indicating growth in the total number of ships and a sustained, or increased, procurement profile for nuclear-powered submarines and aircraft carriers. The company plans to make additional capital expenditures and investments in personnel to meet the current demand requirements, and expects to continue making such expenditures and investments in the future. The company is also exploring growth strategies across its segments through strategic investments and acquisitions to expand and complement existing businesses, expecting to fund these opportunities with cash generated from operations or by raising additional capital through debt, equity or some combination thereof.

The Commercial Operations segment's overall activity primarily depends on the demand and competitiveness of nuclear energy and the demand for critical medical radioisotopes and radiopharmaceuticals. A significant portion of this segment's operations depends on the timing of maintenance outages and the cyclical nature of capital expenditures and major refurbishments for nuclear utility customers, principally in the Canadian market. The medical isotope business will be the platform from which the company plans to launch its Molybdenum-99 product line and a number of future radioisotope-based imaging, diagnostic and therapeutic products. The acquisition of Kinectrics is expected to enable the company to expand its portfolio of products and services in the global nuclear and nuclear medicine markets.

For the year ended December 31, 2025, the Government Operations segment's operating income as a percentage of revenues was 16.8% ³⁶, compared to 17.3% ³⁷ in 2024. The Commercial Operations segment's operating income as a percentage of revenues was 6.8% ³⁸, compared to 8.9% ³⁹ in 2024. Unallocated Corporate expenses increased $4.0 million ⁴⁰ to $48.1 million ⁴¹ in the year ended December 31, 2025 compared to $44.1 million ⁴² in 2024, due to an increase in legal and consulting costs associated with merger and acquisition related activities of $3.9 million ⁴³ and a $7.1 million ⁴⁴ increase in restructuring-related expenditures, partially offset by a decrease in expenditures related to the transformation of information technology infrastructure of $3.2 million ⁴⁵.

The company expects heightened capital spending levels to decline as capital expansion projects are largely complete. Significant projects included the expansion of Government Operations facilities to support increased demand from the U.S. Government and the commercialization of medical radioisotope technology and the expansion of the Cambridge, Ontario, Canada manufacturing plant for heavy commercial nuclear power equipment in the Commercial Operations segment. During the year ended December 31, 2025, purchases of property, plant and equipment were $184,557,000 ⁴⁶.

During the year ended December 31, 2025, the company paid $92.5 million ⁴⁷ in dividends to holders of common stock. As of December 31, 2025, the total remaining share repurchase authorization was $347.6 million ⁴⁸. The company expects cash requirements totaling approximately $12.7 million ⁴⁹ and $2.7 million ⁵⁰ for contributions to its pension plans and other postretirement benefit plans, respectively, in 2026. The company's research and development activities totaled $78.2 million ⁵¹ in the year ended December 31, 2025, including amounts paid for by customers of $64.4 million ⁵².

The company's future business prospects in Canada are dependent upon the continued operation of Canadian nuclear plants and refurbishment of the majority of the plants in Ontario to extend their operating lives. Unfavorable economic conditions, competition from other forms of power generation, increased competition for refurbishment contracts, changes in government policy or operational or project execution issues may lead nuclear plant operators in Canada to cease operations or delay, curtail or cancel proposed or existing life-extension projects. The company also faces risks associated with contractual pricing on fixed-price contracts, where actual costs could exceed projections, resulting in reduced profit or loss.

The company's operations in foreign countries expose it to currency, political and trade risks, including from tariffs, trade barriers, and other protectionist or retaliatory measures. Uncertainty remains with respect to trade policies and treaties between the U.S. and other countries, including Canada, where the company manufactures heavy nuclear components and products for its medical radioisotopes business that may be sold to U.S. customers. New or increased tariffs would increase the cost of products and the components and raw materials that go into making them, which could adversely impact gross margin and make products less competitive.

The company relies on U.S. Government contracts for a substantial percentage of revenue, with U.S. Government contracts comprising approximately 68% ⁵³ of total consolidated revenues for the year ended December 31, 2025. These contracts are subject to annual funding determinations, the continuing availability of Congressional appropriations, and may be terminated or modified at the U.S. Government's convenience. The company faces risks associated with fixed-price contracts, where actual costs could exceed estimates, and during the year ended December 31, 2025, the aggregate impact of changes in estimates increased revenue by $5,544,000 ⁵⁴ and operating income by $4,318,000 ⁵⁵. The company's operations involve the handling of radioactive and hazardous materials, and at December 31, 2025, total environmental accruals including asset retirement obligations were $107.2 million ⁵⁶. The company has underfunded defined benefit pension and postretirement benefit plans with obligations totaling approximately $153.3 million ⁵⁷ at December 31, 2025. The company relies on a limited number of suppliers, including single-source suppliers, for materials used in its products.

Management's message emphasizes the company's position as a leading supplier of nuclear components and fuel to the U.S. Government, with an operating history of more than 100 years. The forward-looking statements in the filing express expectations that the company will continue to benefit from national security spending, with the U.S. Navy's 30-year shipbuilding plan indicating growth in nuclear-powered submarines and aircraft carriers. Management highlights strategic priorities including making additional capital expenditures and investments in personnel to meet current demand requirements, exploring growth strategies through strategic investments and acquisitions such as the acquisitions of A.O.T. and Kinectrics, and developing and commercializing new technologies including medical radioisotopes, advanced nuclear power sources and advanced nuclear reactors. The company expects to recognize approximately 40% ⁵⁸ of the revenue associated with its backlog by the end of 2026.